Navigation Links
Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
Date:9/24/2009

FRAZER, Pa., Sept. 24 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year. The FDA decision on approval of NUVIGIL as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel is expected by December 29, 2009. There currently is no FDA-approved treatment for jet lag disorder.

The NUVIGIL sNDA is based on data from a Phase III pivotal study that evaluated the efficacy and safety of NUVIGIL (50 or 150 mg/day) in 427 healthy adults over three days during travel from the United States to Europe. These data were presented earlier this year at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies.

About NUVIGIL

NUVIGIL, the longer-lasting isomer of modafinil, was launched in the United States in June 2009 and is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy. NUVIGIL is not approved as a treatment for jet lag disorder or its associated symptoms. The NUVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson syndrome, that has been reported in adults and children taking modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (five pe
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015  Epic Sciences announced today that the company ... castrate resistant prostate cancer patients, at the 2015 ... Oncology. This application expands the investigational utility of ... platform to characterize circulating tumor cell (CTC) genomic ... have heterogeneous clonal CTC populations harboring separate genetic ...
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... NEW YORK , May 28, 2015 ... billions developing new drugs and tests, and ... for the instruments that can assist them. This ... research publisher. Kalorama Information said instruments such as ... can assist in the identification of drug ...
Breaking Medicine Technology:Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3The Association for the Advancement of Wound Care Educates the Public 2Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
... data,supporting the clinical development of telaprevir (VX-950), one ... the,treatment of hepatitis C virus (HCV) infection, will ... European Association for the,Study of the Liver (EASL) ... to telaprevir have been accepted for presentation,at the ...
... meeting of the European,Association for the Study of ... /PRNewswire-FirstCall/ --,Schering-Plough Corporation reaffirms its commitment to advancing,the ... (HCV),infection with several key data presentations at the ... 42nd annual meeting,in Barcelona, Spain, April 11-15. A ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 2Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 3Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 4Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 5Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 6Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C 7
(Date:5/30/2015)... May 30, 2015 The IRS released ... 2015, announcing that, “criminals used taxpayer-specific data acquired from ... approximately 100,000 tax accounts through IRS’ “Get Transcript” application. ... and street address.” , “You don’t even have ... to think it was only a matter of time, ...
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 Ready to ... it’s important for all drivers to get their vehicles ready. ... to be prepared. Advanced Driving Systems (ADS) is ready to ... tips on preparing for summer road trips. , When planning ... the following to ensure that the trip goes smoothly and ...
(Date:5/29/2015)... The science of hair restoration has ... to the efforts of internationally recognized hair transplant surgeon ... ARTAS hair restoration and manual FUE techniques to ... anywhere. , A Follicular Unit Extraction (FUE) ... follicle grafts from the donor areas of a patient. ...
(Date:5/29/2015)... Island (PRWEB) May 29, 2015 The ... 2015. The event, now closed to new registration, starts ... Adams. This exciting competitive running event demonstrates the ... to create a public benefit – in this case, ... coastal views around the famed Ocean Drive and passes ...
Breaking Medicine News(10 mins):Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3
... New figures on assisted reproduction technology (ART) in Europe ... use of ICSI (intracytoplasmic sperm injection) to treat infertility, ... Human Reproduction and Embryology (ESHRE) in Barcelona heard today ... using the procedure too often. , In 2005 ...
... Alexandria, Va.A study conducted in Sweden found that more than ... from cancer four or five years earlier reported they were ... they heard this information during the last week of her ... immediately when a wife,s cancer is incurable, including 71 percent ...
... the United States Senate,failed to pass the "Medicare ... a result, a 10.6 percent cut in Medicare ... on July 1, leaving the,physician-patient relationship in great ... Release, go to:, http://www.prnewswire.com/mnr/osteopathic/33934/ , The American ...
... Validates Use of Pharos Innovation,s Proprietary,Device-Free Remote Monitoring Platform to ... ... Medical Costs, NORTHFIELD, Ill., July 8 ... clinical and financial,performance improvement through a device-free remote monitoring platform,announced ...
... an inherent risk in cancer research, particularly in ... misleading results can be mitigated if researchers use ... according to a commentary in the July 8 ... National Cancer Institute . Additionally, the impact of ...
... Help to Lower Health Care Costs, ... Pennsylvania Economy, PITTSBURGH, July 8 The chief ... today at the first,Pennsylvania Insurance Department public hearing about ... be good for customers, health care,providers, and the communities ...
Cached Medicine News:Health News:Researcher say that ICSI may be over-used in some countries 2Health News:Researcher say that ICSI may be over-used in some countries 3Health News:Study finds that significant proportion of men told wife's cancer was incurable late or not at all 2Health News:Audio: Medicare Cuts Threaten Access to Health Care for Seniors 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Highmark and Independence Blue Cross CEOs Say Combination of Highmark and Independence Blue Cross will Provide $1 Billion in New Resources Over Six Years 2
CRP Liquid Conrtols level 2...
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: